Loading...

aTyr Pharma

Nasdaq:LIFE
Snowflake Description

Adequate balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
LIFE
Nasdaq
$29M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The last earnings update was 31 days ago. More info.


Add to Portfolio Compare Print
  • aTyr Pharma has significant price volatility in the past 3 months.
LIFE Share Price and Events
7 Day Returns
16.8%
NasdaqCM:LIFE
-1.4%
US Biotechs
0.9%
US Market
1 Year Returns
-72.2%
NasdaqCM:LIFE
0.6%
US Biotechs
9.6%
US Market
LIFE Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
aTyr Pharma (LIFE) 16.8% 24.3% 14.4% -72.2% -82% -
US Biotechs -1.4% -0.9% -0.8% 0.6% 1.8% 16.4%
US Market 0.9% 4.6% 10.9% 9.6% 39% 47.2%
1 Year Return vs Industry and Market
  • LIFE underperformed the Biotechs industry which returned 0.6% over the past year.
  • LIFE underperformed the Market in United States of America which returned 9.6% over the past year.
Price Volatility
LIFE
Industry
5yr Volatility vs Market
Related Companies

LIFE Value

 Is aTyr Pharma undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for aTyr Pharma. This is due to cash flow or dividend data being unavailable. The share price is $0.64.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for aTyr Pharma's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are aTyr Pharma's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqCM:LIFE PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-1.15
NasdaqCM:LIFE Share Price ** NasdaqCM (2019-04-25) in USD $0.64
United States of America Biotechs Industry PE Ratio Median Figure of 35 Publicly-Listed Biotechs Companies 19.98x
United States of America Market PE Ratio Median Figure of 3,081 Publicly-Listed Companies 18.28x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of aTyr Pharma.

NasdaqCM:LIFE PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:LIFE Share Price ÷ EPS (both in USD)

= 0.64 ÷ -1.15

-0.56x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • aTyr Pharma is loss making, we can't compare its value to the US Biotechs industry average.
  • aTyr Pharma is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does aTyr Pharma's expected growth come at a high price?
Raw Data
NasdaqCM:LIFE PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.56x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
5.1%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 28 Publicly-Listed Biotechs Companies 1.86x
United States of America Market PEG Ratio Median Figure of 2,113 Publicly-Listed Companies 1.57x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for aTyr Pharma, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on aTyr Pharma's assets?
Raw Data
NasdaqCM:LIFE PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $1.10
NasdaqCM:LIFE Share Price * NasdaqCM (2019-04-25) in USD $0.64
United States of America Biotechs Industry PB Ratio Median Figure of 416 Publicly-Listed Biotechs Companies 3.32x
United States of America Market PB Ratio Median Figure of 5,185 Publicly-Listed Companies 1.92x
NasdaqCM:LIFE PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:LIFE Share Price ÷ Book Value per Share (both in USD)

= 0.64 ÷ 1.10

0.58x

* Primary Listing of aTyr Pharma.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • aTyr Pharma is good value based on assets compared to the US Biotechs industry average.
X
Value checks
We assess aTyr Pharma's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. aTyr Pharma has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

LIFE Future Performance

 How is aTyr Pharma expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
5.1%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is aTyr Pharma expected to grow at an attractive rate?
  • Unable to compare aTyr Pharma's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare aTyr Pharma's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.
  • Unable to compare aTyr Pharma's revenue growth to the United States of America market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
NasdaqCM:LIFE Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqCM:LIFE Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts 5.1%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 18.6%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 15.2%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.5%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.1%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqCM:LIFE Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqCM:LIFE Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-12-31
2020-12-31 -31
2019-12-31 0 -25 1
NasdaqCM:LIFE Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 -31 -35
2018-09-30 -37 -40
2018-06-30 -39 -44
2018-03-31 -39 -45
2017-12-31 -42 -48
2017-09-30 -44 -49
2017-06-30 -50 -52
2017-03-31 -54 -55
2016-12-31 -53 -58
2016-09-30 -51 -62
2016-06-30 -46 -59
2016-03-31 -43 -55

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • aTyr Pharma is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Unable to determine if aTyr Pharma is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqCM:LIFE Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from aTyr Pharma Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqCM:LIFE Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-12-31
2020-12-31 -0.99 -0.99 -0.99 1.00
2019-12-31 -0.80 -0.80 -0.80 1.00
NasdaqCM:LIFE Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -1.15
2018-09-30 -1.33
2018-06-30 -1.52
2018-03-31 -1.66
2017-12-31 -1.87
2017-09-30 -2.03
2017-06-30 -2.19
2017-03-31 -2.33
2016-12-31 -2.44
2016-09-30 -2.61
2016-06-30 -2.50
2016-03-31 -2.56

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if aTyr Pharma will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess aTyr Pharma's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
aTyr Pharma has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

LIFE Past Performance

  How has aTyr Pharma performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare aTyr Pharma's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • aTyr Pharma does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare aTyr Pharma's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare aTyr Pharma's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
aTyr Pharma's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from aTyr Pharma Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqCM:LIFE Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 -34.52 12.44 20.39
2018-09-30 -39.67 15.81 21.85
2018-06-30 -43.74 16.73 24.18
2018-03-31 -45.47 17.14 27.01
2017-12-31 -48.21 17.08 30.07
2017-09-30 -49.30 14.57 33.90
2017-06-30 -51.93 14.35 37.16
2017-03-31 -55.17 14.99 40.05
2016-12-31 -57.86 15.09 42.85
2016-09-30 -61.78 15.52 46.37
2016-06-30 -59.29 15.63 43.72
2016-03-31 -55.00 14.90 39.91
2015-12-31 -47.99 13.11 33.10
2015-09-30 -37.53 10.99 24.78
2015-06-30 -32.97 9.24 21.45
2015-03-31 -27.61 7.56 17.58
2014-12-31 -24.77 6.78 16.78
2014-09-30 -24.30 6.29 16.55
2013-12-31 -21.65 5.71 13.83
2012-12-31 -17.61 4.85 7.75

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if aTyr Pharma has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if aTyr Pharma has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if aTyr Pharma improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess aTyr Pharma's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
aTyr Pharma has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

LIFE Health

 How is aTyr Pharma's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up aTyr Pharma's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • aTyr Pharma is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • aTyr Pharma's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of aTyr Pharma's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 3.2x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from aTyr Pharma Company Filings, last reported 3 months ago.

NasdaqCM:LIFE Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 33.65 16.03 49.55
2018-09-30 38.99 17.81 55.96
2018-06-30 45.38 19.57 64.33
2018-03-31 54.50 19.98 74.10
2017-12-31 64.25 19.73 85.12
2017-09-30 72.29 14.75 90.38
2017-06-30 40.03 14.58 57.22
2017-03-31 50.71 9.57 61.93
2016-12-31 62.80 9.54 72.15
2016-09-30 73.99 2.64 70.53
2016-06-30 86.57 3.49 83.93
2016-03-31 100.43 4.32 86.05
2015-12-31 115.05 5.14 95.54
2015-09-30 129.16 5.95 108.80
2015-06-30 139.34 6.74 102.96
2015-03-31 43.29 9.51 54.51
2014-12-31 4.61 10.28 15.85
2014-09-30 9.63 11.03 23.45
2013-12-31 27.08 6.89 36.46
2012-12-31 -1.33 4.50 3.68
  • aTyr Pharma's level of debt (47.6%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (25.5% vs 47.6% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • aTyr Pharma has sufficient cash runway for 1.6 years based on current free cash flow.
  • aTyr Pharma has sufficient cash runway for 1.6 years if free cash flow continues to reduce at historical rates of -7.8% each year.
X
Financial health checks
We assess aTyr Pharma's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. aTyr Pharma has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

LIFE Dividends

 What is aTyr Pharma's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from aTyr Pharma dividends. Estimated to be 0% next year.
If you bought $2,000 of aTyr Pharma shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate aTyr Pharma's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate aTyr Pharma's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqCM:LIFE Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 20 Stocks 2.4%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2008 Stocks 2.4%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqCM:LIFE Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as aTyr Pharma has not reported any payouts.
  • Unable to verify if aTyr Pharma's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of aTyr Pharma's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as aTyr Pharma has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of aTyr Pharma's dividends in 3 years as they are not expected to pay a notable one for United States of America.
X
Income/ dividend checks
We assess aTyr Pharma's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can aTyr Pharma afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. aTyr Pharma has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

LIFE Management

 What is the CEO of aTyr Pharma's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Sanjay Shukla
COMPENSATION $1,380,465
AGE 46
TENURE AS CEO 1.4 years
CEO Bio

Dr. Sanjay S. Shukla, M.D., M.S., has been the Chief Executive Officer and President at aTyr Pharma, Inc. since November 1, 2017. Dr. Shukla served as Chief Medical Officer at aTyr Pharma, Inc. from March 2016 to November 1, 2017. Dr. Shukla served as Vice President and Global Head of Integrated Medical Services for Novartis, he led global medical affairs operations, with oversight for all pharma general medicines therapies, both inline and in development. These included brands such as Gilenya, Cosentyx and Entresto. In addition, Dr. Shukla led the creation and development of the Real World Evidence Center for Excellence as well as incubating the Digital Strategy group within Global Medical Affairs. Previously, he served as Chief Executive Officer of RxMd, a clinical development consultancy that assisted in advancing proof of concept for early stage drug candidates. Prior to that, Dr. Shukla served in a variety of clinical development, data analytics and drug safety roles at Vifor Pharma and Aspreva Pharmaceuticals. He serves as a Member of Advisory Board at nPruv, Inc. and RxMD. Dr. Shukla received his M.D. from Howard University College of Medicine and his Bachelors of Science in Microbiology and Master of Science in Epidemiology and Biostatistics from the University of Maryland.

CEO Compensation
  • Sanjay's compensation has been consistent with company performance over the past year.
  • Sanjay's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the aTyr Pharma management team in years:

1.3
Average Tenure
56
Average Age
  • The average tenure for the aTyr Pharma management team is less than 2 years, this suggests a new team.
Management Team

Sanjay Shukla

TITLE
President
COMPENSATION
$1M
AGE
46
TENURE
1.4 yrs

Jill Broadfoot

TITLE
CFO & Principal Accounting Officer
COMPENSATION
$535K
AGE
56
TENURE
0.8 yrs

John Mendlein

TITLE
Strategic Advisor & Director
COMPENSATION
$146K
AGE
58
TENURE
1.3 yrs

David King

TITLE
Scientific Consultant
COMPENSATION
$717K
AGE
59
TENURE
0.3 yrs

Xiang-Lei Yang

TITLE

Mark Johnson

TITLE
Senior Director of Investor Relations

Nancy Krueger

TITLE
General Counsel & Corporate Secretary
AGE
50
TENURE
4.5 yrs

Ying Buechler

TITLE
Executive Director of Biologics Development & Manufacturing

Melissa Ashlock

TITLE
Senior Advisor
COMPENSATION
$1M
AGE
60
TENURE
7.9 yrs

Sanuj Ravindran

TITLE
Business Advisor
COMPENSATION
$1M
AGE
46
TENURE
1.3 yrs
Board of Directors Tenure

Average tenure and age of the aTyr Pharma board of directors in years:

9.5
Average Tenure
61
Average Age
  • The tenure for the aTyr Pharma board of directors is about average.
Board of Directors

John Clarke

TITLE
Chairman
COMPENSATION
$113K
AGE
64
TENURE
13.6 yrs

Sanjay Shukla

TITLE
President
COMPENSATION
$1M
AGE
46
TENURE
1.4 yrs

John Mendlein

TITLE
Strategic Advisor & Director
COMPENSATION
$146K
AGE
58
TENURE
8.8 yrs

Jim Blair

TITLE
Independent Director
COMPENSATION
$71K
AGE
78
TENURE
8.3 yrs

Tim Coughlin

TITLE
Director
COMPENSATION
$92K
AGE
51
TENURE
2 yrs

Amir Nashat

TITLE
Independent Director
COMPENSATION
$68K
AGE
45
TENURE
12.4 yrs

Paul Schimmel

TITLE
Director
COMPENSATION
$57K
AGE
77
TENURE
13.6 yrs

Bruce Beutler

TITLE
Member of Scientific Advisory Board
TENURE
9.7 yrs

Osamu Nureki

TITLE
Member of Scientific Advisory Board
TENURE
9.6 yrs

Floyd Bloom

TITLE
Member of Scientific Advisory Board
AGE
81
TENURE
9.5 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
12. Feb 19 Sell Sofinnova Investment, Inc. Company 16. May 18 08. Jun 18 -1,694,528 $0.96 $-1,631,830
26. Dec 18 Buy John Mendlein Individual 20. Dec 18 21. Dec 18 245,000 $0.42 $103,247
29. Nov 18 Buy Paul Schimmel Individual 26. Nov 18 26. Nov 18 147,225 $0.54 $79,796
21. Sep 18 Buy Jill Church Individual 19. Sep 18 20. Sep 18 64,000 $0.84 $52,855
18. Sep 18 Buy Jill Church Individual 14. Sep 18 14. Sep 18 26,000 $0.73 $19,055
05. Sep 18 Buy Paul Schimmel Individual 31. Aug 18 04. Sep 18 42,749 $0.76 $31,461
31. Aug 18 Buy Paul Schimmel Individual 29. Aug 18 30. Aug 18 164,411 $0.76 $121,573
21. May 18 Buy Paul Schimmel Individual 18. May 18 18. May 18 150,000 $1.00 $149,445
16. May 18 Sell EcoR1 Capital, LLC Company 14. May 18 16. May 18 -3,209,316 $1.72 $-2,999,056
X
Management checks
We assess aTyr Pharma's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. aTyr Pharma has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

LIFE News

Simply Wall St News

LIFE Company Info

Description

aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its therapeutic candidate pipeline includes ATYR1923 candidate, a fusion protein comprising the immuno-modulatory domain of histidyl tRNA synthetase fused of a human antibody that is in Phase 1b/2a clinical trial for treating patients with interstitial lung diseases (ILDs), such as pulmonary sarcoidosis; and in Phase 1 clinical trial to treat chronic hypersensitivity pneumonitis and connective tissue disease ILD. The company has a collaboration with the University of Nebraska Medical Center for the development of neuropilin-2 receptor biology; and a research collaboration and option agreement with CSL Behring for the development of product candidates derived from up to four tRNA synthetases. The company was founded in 2005 and is headquartered in San Diego, California.

Details
Name: aTyr Pharma, Inc.
LIFE
Exchange: NasdaqCM
Founded: 2005
$29,275,092
45,742,332
Website: http://www.atyrpharma.com
Address: aTyr Pharma, Inc.
3545 John Hopkins Court,
Suite 250,
San Diego,
California, 92121,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM LIFE Common Shares Nasdaq Capital Market US USD 08. May 2015
DB 471 Common Shares Deutsche Boerse AG DE EUR 08. May 2015
Number of employees
Current staff
Staff numbers
42
aTyr Pharma employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/26 03:02
End of day share price update: 2019/04/25 00:00
Last estimates confirmation: 2019/03/30
Last earnings filing: 2019/03/26
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.